38 results about "Prostaglandin f" patented technology

The present invention describes novel methods for using 9-deoxy-2′,9-α-methano-3-oxa-4,5,6-trinor-3,7-(1′,3′-interphenylene)-13,14-dihydro-prostaglandin F1 (also known as Treprostinil) or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and / or prevention of foot ulcers in subjects with diabetic neuropathy. The invention also relates to kits for treatment and / or prevention of foot ulcers, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.

A method for preparing a prostaglandin F analogue represented by the following formula (I) is disclosed,wherein R1, and are as defined in the specification.

A method for the preparation of a prostaglandin F analogue presented by the following formula (I):is disclosed, whereinR1, G1, and are as defined in the specification. A novel intermediate compound for the preparation of a prostaglandin F analogue is also disclosed.

A method for preparing a prostaglandin F-type compound. Also disclosed is an intermediate of the following formula (II) compound wherein R′, X and A have the same meaning as given in the specification.

The present invention is a method of treating blepharospasm with a prostaglandin derivative, comprising the steps of (a) providing a predetermined amount of prostaglandin derivative; and (b) applying the prostaglandin derivative in a predetermined position. The prostaglandin derivative is preferably in the form of latanoprost wherein the chemical composition of latanoprost is a prostaglandin F.sub.2.alpha derivative which has the chemical name isopropyl-(Z)-7[(1R,2R,3R,5S)3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl I]cyclo-pentyl]-5-heptenoate. The dosage of the prostaglandin derivative is generally in the range of 1.5 ug to 4.5 ug which is equivalent to 1 to 3 drops aqueous solution for human eye

The invention relates to a synthesis method for dinoprostone (prostaglandin PGE2), and in particular a method for converting prostaglandin F (for example, PGF2 alpha) to prostaglandin E (for example, PGE2). The method comprises the following steps of: oxidizing 11-site and 15-site hydroxy-protected prostaglandin PGF2 alpha to hydroxy-protected PGE2 by environment-friendly pyridine sulphur trioxide, and then hydrolyzing and de-protecting in citric acid aqueous solution to obtain PGE2. The method has the characteristics of being green and environment-friendly, safe to operate, convenient in after-treatment, short in production cycle, low in cost, and high in productivity and purity, as well as is suitable for industrialized production.

A solid-phase immunoassay for 6-keto-Prostaglandin F1α, the stable hydrolysis product of prostacyclin (Prostaglandin I2) is disclosed. Prostacyclin, a potent vasodilator with anti-platelet and anti-proliferative properties is an effective treatment for primary pulmonary hypertension and pulmonary arterial hypertension associated with scleroderma and scleroderma-like syndrome. Levels of 6-keto-Prostaglandin F1α can be directly correlated with levels of prostacyclin. Therefore, 6-keto-Prostaglandin F1α has become the indicator of choice to measure prostacyclin levels. The single step immunoassay for 6-keto-Prostaglandin F1α uses the bioluminescent protein, aequorin as a label. Analyte-label conjugates were constructed by linking the carboxyl group of 6-keto-Prostaglandin F1α and lysine residues of aequorin by chemical conjugation methods. The binding properties of 6-keto-Prostaglandin F1α towards its antibody and the bioluminescent properties of aequorin are retained in the conjugate. The concentration of 6-keto-Prostaglandin F1α after extraction from plasma shows good correlation with the concentration of 6-keto-Prostaglandin F1α obtained without prior extraction of the same plasma sample. The assay allows the measurement of 6-keto-Prostaglandin F1α directly in plasma without any pre-treatment of the samples, which results in a much simpler method with a faster assay time.

The invention concerns a new process for the preparation of prostaglandin derivatives, in particular prostaglandin F2α derivatives, for example bimatoprost, latanoprost and travoprost, the new intermediates of said process and their use in the preparation of prostagblandin derivatives.

The invention relates to a producing method of prostaglandin F-type derivants as shown in a right formula (I), wherein R1 and a definition are as shown in a specification.

An embryo that is transferred into the uterus of a recipient female is protected from toxic effects of prostaglandin F2α by exposing the embryo, or an oocyte from which the embryo is produced, to a prostaglandin antagonist.

The present invention describes novel methods for using 9-deoxy-2', 9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylene)-13,14-dihydro-prostaglandin F1 (also known as Treprostinil) or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and / or prevention of foot ulcers in subjects with diabetic neurophathy. The invention also relates to kits for treatment and / or prevention of foot ulcers, comprising an effective amount of treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.

An embryo that is transferred into the uterus of a recipient female is protected from embryotoxic effects of prostaglandin F2α by exposing the embryo to a prostaglandin antagonist.

Disclosed is a method for treating macular degeneration in a mammalian subject, which comprises administering to the subject in need thereof an effective amount of a 15-keto-prostaglandin compound such as 13,14-dihydro-15-keto-20-ethyl-prostaglandin F2α isopropyl ester.

The present invention relates to a process for preparing a prostaglandin derivative and an intermediate therefor. In accordance with the present invention, the prostaglandin F (PGF) derivative can be efficiently prepared with high purity by removing the protecting group of a protected prostaglandin E (PGE) derivative obtained from conjugate addition and then stereoselectively reducing the ketone group on the cyclopentanone ring of the PGE derivative.

The invention relates to a specific monoclonal antibody hybridoma cell strain WXX-2 of antiprostaglandin F2alpha and application thereof and belongs to the technical field of clinical detection. The specific monoclonal antibody hybridoma cell strain WXX-2 of antiprostaglandin F2alpha provided by the invention has been preserved in CGMCC with the preservation number of CGMCC No. 13087. The specific monoclonal antibody of antiprostaglandin F2alpha is secreted by the specific monoclonal antibody hybridoma cell strain WXX-2 of antiprostaglandin F2alpha. The hybridoma cell strain WXX-2 can secrete a monoclonal antibody which has relatively good specificity and relatively high sensitivity on prostaglandin F2alpha, and the 50% inhibition concentration IC50 on the prostaglandin F2alpha is 1.80 [mu]g / L. The specific monoclonal antibody can be used for specific detection of the prostaglandin F2alpha in clinical detection.

The present invention relates to a process for preparing a prostaglandin derivative and an intermediate therefor. In accordance with the present invention, the prostaglandin F (PGF) derivative can be efficiently prepared with high purity by removing the protecting group of a protected prostaglandin E (PGE) derivative obtained from conjugate addition and then stereoselectively reducing the ketone group on the cyclopentanone ring of the PGE derivative.

A method for inhibiting hair growth in mammals using compositions containing FP receptor antagonists (e.g., prostaglandin F analogs that are block activation of the FP receptor). The compositions can be applied topically to the skin and / or hair. The compositions can arrest hirsutism or hypertrichosis, reverse hirsutism and hypertrichosis, and further prevent hair growth. These compositions can also be used to protect hair from chemical or radiation-induced alopecia or hair loss. These compositions can also be used to inhibit pigmentation of the hair or skin.

The invention relates to compositions which are useful for inhibiting prostaglandin F2α receptor. The compositions include, but are not limited to, linear peptides, peptide analogs, and peptidomimetics. Methods of using the compositions of the invention to treat preterm labor and dysmenorrhea are disclosed.

AKR1B1 (EC 1.1.1.21) is an aldose reductase that has mainly been associated with the polyol pathway, and more recently with lipid deperoxidation. We have discovered that the primary activity of this enzyme is rather a PGFS activity, catalyzing the transformation of PGH2 into PGF2α. AKR1B1 as a therapeutic target, and method for modulating its expression and activity are provided. Methods for regulating the expression and activity of PGF2α are also provided.

Cutaneous ulcers and non-healing skin wounds are a route for infection and represent a source of significant morbidity and mortality for humans. The present disclosure provides methods and compositions for treating, healing or preventing cutaneous ulcers and non-healing cutaneous wounds via the topical application of an effective amount of a nitric oxide (NO)-donating prostaglandin F2-alpha (PGF2-alpha) analog directly to the affected ulcer or non-healing cutaneous wound of a human in need of such treatment

A convergent synthesis of the prostaglandin F2α analogues, travoprost and bimatoprost, was developed employing Julia-Lythgoe olefination of the structurally advanced phenylsulfone with an enantiomerically pure aldehyde ω-chain synthon. The novel convergent strategy allows the synthesis of a whole series of prostaglandin analogues of high purity from a common and structurally advanced prostaglandin intermediate.

AKR1B1 (EC 1.1.1.21) is an aldose reductase that has mainly been associated with the polyol pathway, and more recently with lipid deperoxidation. We have discovered that the primary activity of this enzyme is rather a PGFS activity, catalyzing the transformation of PGH2 into PGF2α. AKR1B1 as a therapeutic target, and method for modulating its expression and activity are provided. Methods for regulating the expression and activity of PGF2α are also provided.

A stable liposomal formulation for ophthalmic drug delivery. The formulation comprises a liposome comprising at least one lipid bilayer comprising lecithin; and prostaglandin F encapsulated within the liposome 2α . Also provided herein is a method of treating eye diseases with the formulation.

The invention discloses an application of citrus fruit volatile oil in preparation of food and medicine that regulate a human endocrine system and are used to treat hemorrhoid. The functional hemorrhoid can be treated by inhibiting the secretion of prostaglandin F2alpha, increasing the secretion of prostaglandin E2, reducing the expression level of inflammatory factors, improving the body's antioxidant capacity, adjusting the human endocrine system, and stimulating the hormone secretion of glands in the body to return to normal levels The product makes full use of the peel of citrus fruits, avoids waste of resources, and can effectively treat hemorrhoid without temporary eating a laxative to improve hemorrhoid.

The invention discloses application of citrus fruit volatile oil to preparation of food and medicine for regulating a human endocrine system and treating functional constipation. By inhibiting the secretion of prostaglandin F2[alpha], improving the secretion of prostaglandin E2, lowering the expression level of inflammatory factors and improving the antioxidant capacity of an organism, the human endocrine system is regulated, hormone secretion of glands in the body is stimulated to return to a normal level, and thus the functional constipation is treated. The peels of citrus fruits are fully utilized, the waste of resources is avoided, the functional constipation can be effectively treated, and people do not need to temporarily eat laxative to relieve the constipation.